Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (114)	10/5/1998 2:21:00 PM
From: Jim Oravetz	Read Replies (2) of 370

Vion gets patents for 2 products 10/2/1998 New Haven Register By Wayne E. Travers Jr. NEW HAVEN - Vion Pharmaceuticals has been granted patents for a cancer-fighting agent and an anti-viral compound, company spokesman Tom Mizelle said Thursday. Mizelle said the U.S. Patent and Trademark Office issued one patent for the composition and use of two anti-cancer agents, known as 3-AP and 3-AMP, that work by arresting the growth of cancer cells. Both are variants of a Vion drug, Triapine, which is now being tested for safety on healthy human subjects. The second patent was issued for the use of an anti-viral compound found to be effective in the treatment of human immunodeficiency virus, or HIV, when combined with other drugs, including AZT. Vion holds an exclusive license for the compound, called B-L-FD4C, granted by Yale University. Yale received patents in 1997 on B-L-FD4C for its use in combating the hepatitis B virus. Vion also received "notices of allowance," which designate a process or substance as patentable and is a precursor to a patent being granted. Those notices apply to the process of synthesizing 3-AP and 3-AMP and developing B-L- FD4C. John Spears, Vion's chief executive officer, said the grantings of the patents and notices of allowance "further increase the strength and value of Vion's already extensive intellectual property portfolio."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next